Search results
CHEST develops trustworthy, evidence-based clinical practice guidelines on the diagnosis and treatment of chest disease states with the help of CHEST members, volunteers, leaders, and staff. Help create high-quality, relevant clinical pulmonary guidelines.
- Thoracic Oncology Guidelines
This CHEST guideline series presents recommendations for the...
- CHEST Guidelines
The Guidelines Oversight Committee is responsible for...
- Thoracic Oncology Guidelines
The Guidelines Oversight Committee is responsible for overseeing the preparation of evidence-based clinical practice guidelines and expert panel reports on behalf of CHEST in the areas of cardiopulmonary medicine and surgery, critical care, sleep medicine, and related disciplines. Underpinning the committee’s work is their mission to optimize ...
This CHEST guideline series presents recommendations for the diagnosis, treatment, and management of patients with lung cancer, covering the full spectrum of care from initial evaluation to palliative and end-of-life care. Additional recommendations include screening, chemoprevention, and treatment of tobacco use in patients with lung cancer.
GesEPOC guidelines recommend personalized treatment based on risk factors and symptoms. For low-risk patients with inadequate control, dual bronchodilation therapy is advised. High-risk patients on dual bronchodilation may need triple therapy (LABA + LAMA + CI) in a single inhaler [ 9 ] ( Figure 1 ).
Pharmacologic treatment for COPD aims to improve quality of life (QOL) and control symptoms while reducing the frequency of exacerbations. The purpose of this clinical practice guideline is to address specific clinically important questions regarding the pharmacologic management of COPD.
Pharmacologic treatment for COPD aims to improve quality of life (QOL) and control symptoms while reducing the frequency of exacerbations. The purpose of this clinical practice guideline is to address specific clinically important questions regarding the pharmacologic management of COPD.
The goals of treatment are nearly identical between the two documents: reduction of symptoms, improvement in patients’ health status, prevention of exacerbations, and decreases in mortality. GOLD and CTS both recommend evaluating patients with treatable traits of dyspnea and exacerbations to personalize therapy.
